New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
11:04 EDTAUXL, TKMR, KMR, SWI, TITN, BSX, NOAHActive equity options trading on open
High option volume stocks: TKMR KMR SWI TITN BSX KMI DF NOAH AMLP AUXL
News For AUXL;TKMR;KMR;SWI;TITN;BSX;NOAH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 9, 2014
14:24 EDTTKMRCDC head compares Ebola to AIDS, Washington Post says
Subscribe for More Information
14:13 EDTTKMRFirst Ebola vaccine trial in West Africa started, NBC News reports
Subscribe for More Information
12:06 EDTTKMRLakeland Industries continues surge amid Ebola fears
Subscribe for More Information
09:20 EDTAUXLOn The Fly: Pre-market Movers
Subscribe for More Information
09:00 EDTAUXLEndo says its not in position to give FY15
Subscribe for More Information
08:49 EDTAUXLEndo sees low-double digit revenue growth with Auxilium portfolio
Subscribe for More Information
08:37 EDTAUXLEndo expects Auxilium acquisition immediately accretive post close
Endo (ENDP) says the deal will provided expected annual run rate synergies of up to $175M by the first year after closing versus Auxilium's (AUXL trailing 12-month actuals as of June 30. Says synergies include Auxilium's $75M reduction in annual operating expenses previously announced. Says the deal is expected to "significantly'" enhance Endo's branded pharmaceutical business with the addition of Auxilium's men's health products and development portfolio. Says the agreement is designed to "accelerate growth" and maximize value of Auxilium's products by leveraging strengths of combined company. Says combined company will be "well positioned" to drive organic growth for branded pharmaceutical business. Says deal creates a "strong" margin profile and an enhanced near-and long-term revenue growth profile. Comments taken from the company's slide presentation regarding its combination with Auxilium.
07:49 EDTAUXLEndo and Auxilium host a joint conference call
Subscribe for More Information
07:30 EDTAUXLQLT Inc. says re-engaging assessment of options after Auxilium deal ended
Subscribe for More Information
06:52 EDTAUXLQLT Inc. merger with Auxilium terminated for superior proposal from Endo
Subscribe for More Information
06:32 EDTAUXLEndo to acquire Auxilium in cash, stock transaction for approximately $2.6B
Endo (ENDP) and Auxilium Pharmaceuticals (AUXL) announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction. The boards of both companies have unanimously approved the transaction, which is valued at $2.6B, including the repayment and assumption of debt. The transaction will include an election mechanism for Auxilium stockholders to elect cash and stock, all-stock or all-cash consideration, subject to proration in accordance with the terms of the definitive agreement. The per share consideration represents a premium of 55% to Auxilium's closing price on September 16, the day Endo made public its proposal for Auxilium. Subject to aggregate cash and equity consideration limits, Auxilium stockholders may elect one of three options with respect to transaction consideration: 100% equity which equates to 0.488 Endo shares per Auxilium share, 100% cash which equates to $33.25 per Auxilium share or a standard election of an equal mix of $16.625 in cash and 0.244 Endo shares per Auxilium share. The total cash consideration will not exceed 50% of the total equity value and the equity consideration will not exceed 75% of the total equity value. The transaction is expected to close in 1H15 and is subject to the approval of Auxilium's stockholders, regulatory approval in the U.S. and certain other jurisdictions, and other customary closing conditions.
06:31 EDTAUXLEndo to acquire Auxilium in cash, stock transaction for approximately $2.6B
Subscribe for More Information
05:50 EDTTKMRStocks with implied volatility movement; ARWR TKMR
Stocks with implied volatility movement; Arrowhead (ARWR) 158, Tekmira (TKMR) 130 according to iVolatility.
October 8, 2014
20:03 EDTBSXBoston Scientific confirms FDA panel votes for WATCHMAN device
After reviewing updated data and analysis for the Boston Scientific Corporation WATCHMAN Left Atrial Appendage Closure Device, the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee voted in favor of the Device. By a vote of 6 to 5, with 1 abstention, the panel concluded that the benefits of the WATCHMAN Device outweigh the potential risks. The panel voted that there is reasonable assurance that the device is safe, with a 12 yes to 0 no vote. On the question of reasonable assurance of effectiveness, the panel vote was unfavorable with a 6 yes to 7 no vote. The panel provided substantial input and guidance related to the proposed Indications for use and target patient population. There was widespread agreement among the panel members that the device provides a much needed alternative to long-term anticoagulation for some patients. While not bound by this vote, the FDA takes Advisory Panel comments and recommendations into account when reviewing the WATCHMAN Device application. The company is committed to working with the FDA to address the panel's comments.
18:42 EDTBSXBoston Scientific Watchman Device receives votes from FDA panel, Dow Jones says
The FDA Panel voted 6 to 5 that benefits of Boston Scientific's Watchman device outweigh the risks, Dow Jones reports. The panel voted 12 to 0 that the Watchman device is safe, and the panel voted 7 to 6 that the Watchman device is not effective, Dow Jones added.
11:59 EDTTKMRTekmira volatility increases after Ebola patient dies
Subscribe for More Information
11:22 EDTTKMRChimerix falls after Ebola patient taking experimental drug dies
Shares of Chimerix (CMRX) are moving lower after the Texas Health Presbyterian Hospital Dallas announced that Thomas Eric Duncan succumbed to Ebola. Duncan was being treated with Chimerix's experimental drug Brincidofovir. Shares of Chimerix dropped 9% following the news to $30.19. Other makers of experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT) and BioCryst (BCRX).
07:24 EDTBSXFDA Circulatory Systems Devices Panel to hold a meeting
The Committee discusses, makes recommendations and votes on information related to the Pre-Market Approval Application regarding Boston Scientificís WATCHMAN Left Atrial Appendage (LAA) Closure Technology in a meeting being held in Gaithersburg, Maryland on October 8 at 8 am. Webcast Link
October 7, 2014
13:45 EDTTKMRTekmira at 5-session lows, levels to watch
Subscribe for More Information
13:28 EDTTKMRTekmira down 5% after report says Chimerix drug used on NBC journalist
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use